HLA-C and neoplasm: The reduced percentage of CD11+Ly6G+myeloid cells and the accumulation of differentiating monocytes at the intermediate state with phenotype of Ly6C+MHC+ in tumor were induced by the combination therapy, thereby, enhancing the anti-tumor activity (162).